Test Input #11: "Omega Neurotech" - The Ultimate Stress Test

Financials:

LTM Revenue: $320 million

LTM EBITDA: -$85 million (heavy neuroscience R&D)

Growth Rate: 140% year-over-year (explosive)

Comparables:

Industry Revenue Multiple: 28.0x (high-growth neurotech)

Industry EBITDA Multiple: N/A (negative)

Blended with AI proxy companies at 40% weight (AI multiple: 32.0x)

Capital & Shares:

Pre-IPO Shares: 45 million

Founder super-voting shares: 12M shares with 20x votes

Employee pool: 8M unexercised options (avg strike: $4.50)

Complex Convertible Securities:

Series D SAFEs: $200M converts at lower of $18.00 or 80% of IPO price

Venture Debt: $150M at 8% interest, converts at $22.00 if IPO > $25.00

Government Loan: $75M converts to 3.75M shares at IPO price if FDA approval milestone met (70% probability)

Contingent Dilution:

Acquisition Earnout: If revenue > $500M in Year 2, issue 6.2M shares to acquired company founders

Performance Warrants: Management gets 4.8M shares at $15.00 if stock trades > $40.00 for 90 days post-IPO (45% probability)

Strategic Elements:

Google has right to purchase 5.5M shares at IPO price + 5% premium

Pfizer co-development agreement includes 2.2M share grant at $0.01 if Phase 3 succeeds (60% probability)

Sovereign Wealth Fund anchor order: $300M at IPO price

IPO Structure:

Primary Raise: $750 million (build quantum-neuro imaging facilities)

Secondary Sale: 12.5 million shares (VC partial exits)

Greenshoe: 20% (aggressive)

Target Float: 18-22%

Market Conditions:

Base IPO Discount: 15%

Sector window: Hot neurotech/AI convergence

Investor appetite: "FOMO-driven" per bankers

Additional Complexities:

NOLs: $420 million tax loss carryforwards

Royalty Stream: Pays 3.5% of revenue to Stanford through 2040

Lease obligations: $280M for specialized lab space

Litigation contingency: 25% chance of losing patent case requiring $120M payment

Control Requirements:

Founders must retain >45% voting power post-IPO

CEO has golden share veto on certain M&A

Test Requirements:

Handle multiple convertible instruments with different triggers

Account for probability-weighted contingent liabilities

Incorporate strategic partner premiums

Manage extreme growth vs. massive losses

Ensure founder control amidst complex dilution

Price to achieve massive $750M raise while maintaining credibility